IL170601A - Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection - Google Patents

Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection

Info

Publication number
IL170601A
IL170601A IL170601A IL17060105A IL170601A IL 170601 A IL170601 A IL 170601A IL 170601 A IL170601 A IL 170601A IL 17060105 A IL17060105 A IL 17060105A IL 170601 A IL170601 A IL 170601A
Authority
IL
Israel
Prior art keywords
cancer
viral infection
therapeutic treatment
chronic viral
myxoma virus
Prior art date
Application number
IL170601A
Other languages
English (en)
Inventor
John C Bell
Grant Mcfadden
Original Assignee
John C Bell
Robarts Res Inst
Grant Mcfadden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John C Bell, Robarts Res Inst, Grant Mcfadden filed Critical John C Bell
Publication of IL170601A publication Critical patent/IL170601A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL170601A 2003-03-07 2005-08-31 Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection IL170601A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45252103P 2003-03-07 2003-03-07
US45539303P 2003-03-18 2003-03-18
PCT/CA2004/000341 WO2004078206A1 (en) 2003-03-07 2004-03-08 Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection

Publications (1)

Publication Number Publication Date
IL170601A true IL170601A (en) 2010-11-30

Family

ID=32965588

Family Applications (1)

Application Number Title Priority Date Filing Date
IL170601A IL170601A (en) 2003-03-07 2005-08-31 Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection

Country Status (11)

Country Link
US (2) US7582614B2 (enExample)
EP (1) EP1601376B1 (enExample)
JP (2) JP4800924B2 (enExample)
KR (1) KR101116858B1 (enExample)
AU (1) AU2004216928C1 (enExample)
CA (1) CA2517147C (enExample)
IL (1) IL170601A (enExample)
MX (1) MXPA05009526A (enExample)
NZ (1) NZ541951A (enExample)
RU (1) RU2362584C2 (enExample)
WO (1) WO2004078206A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1601376B1 (en) * 2003-03-07 2012-05-30 Robarts Research Institute Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
NZ560840A (en) * 2005-03-07 2009-07-31 Robarts Res Inst Use of a combination of myxoma virus and rapamycin for therapeutic treatment
WO2007143538A2 (en) * 2006-06-01 2007-12-13 Robarts Research Institute Pike-a enhances infection by myxoma virus
KR20090014364A (ko) * 2006-06-01 2009-02-10 로바츠 리서치 인스티튜트 암 치료용 점액종 바이러스 변이종
DK2717887T3 (en) 2011-06-09 2018-04-09 Univ Florida Methods for treating or preventing graft-versus-host disease
CN109982709A (zh) * 2016-11-17 2019-07-05 Vcn生物科学有限公司 病毒载体在治疗视网膜母细胞瘤中的用途
CA3074901A1 (en) 2017-09-11 2019-03-14 Imba - Institut Fur Molekulare Biotechnologie Gmbh Tumor organoid model
WO2019177438A1 (ko) * 2018-03-16 2019-09-19 바이로큐어 주식회사 암 치료를 위한 레오바이러스 및 믹소마폭스 바이러스의 병용
RU2699754C1 (ru) * 2018-05-08 2019-09-09 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский национальный исследовательский государственный университет имени Н.Г. Чернышевского" Флуоресцирующая клеточная линия глиомы и способ её получения
US12128099B2 (en) 2018-05-25 2024-10-29 Bioventures, Llc Myxoma virus compositions and methods of use
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020036341A1 (ko) * 2018-08-17 2020-02-20 바이로큐어 주식회사 암 치료를 위한 다람쥐폭스 바이러스 및 믹소마폭스 바이러스의 병용
WO2020051248A1 (en) * 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
WO2020106880A1 (en) 2018-11-20 2020-05-28 Bioventures, Llc Cells for the production of viruses and methods of using the same
US11591616B1 (en) 2019-04-22 2023-02-28 Colorado State University Research Foundation Apoptotic upregulation by myxoma virus expressing walleye dermal sarcoma virus orfC

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
WO1997026904A1 (en) 1996-01-25 1997-07-31 Medical Research Council Treatment of non-neuronal cancer using hsv mutant
WO1999004026A2 (en) 1997-07-18 1999-01-28 Chiron Corporation Lentiviral vectors
IL135507A0 (en) 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
ES2153284B1 (es) 1998-06-10 2001-09-01 Fundacion Para El Estudio Y De Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos.
CN1477964A (zh) 1999-04-15 2004-02-25 应用病毒治疗肿瘤
CA2378567A1 (en) * 1999-07-12 2001-01-18 Viron Therapeutics, Inc. Novel myxoma genes for immune modulation
EP1601376B1 (en) * 2003-03-07 2012-05-30 Robarts Research Institute Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection
WO2007143545A2 (en) 2006-06-01 2007-12-13 Robarts Research Institute Tnf signaling in myxoma virus treatments

Also Published As

Publication number Publication date
EP1601376B1 (en) 2012-05-30
RU2005131020A (ru) 2006-03-10
AU2004216928B2 (en) 2007-03-08
NZ541951A (en) 2008-03-28
US7582614B2 (en) 2009-09-01
WO2004078206A1 (en) 2004-09-16
MXPA05009526A (es) 2005-12-15
EP1601376A1 (en) 2005-12-07
JP2006519789A (ja) 2006-08-31
AU2004216928C1 (en) 2007-03-08
JP2011157399A (ja) 2011-08-18
JP4800924B2 (ja) 2011-10-26
US8227440B2 (en) 2012-07-24
AU2004216928A1 (en) 2004-09-16
US20090317362A1 (en) 2009-12-24
CA2517147A1 (en) 2004-09-16
CA2517147C (en) 2011-06-14
KR20050111349A (ko) 2005-11-24
US20060263333A1 (en) 2006-11-23
KR101116858B1 (ko) 2012-03-06
RU2362584C2 (ru) 2009-07-27
HK1081099A1 (en) 2006-05-12

Similar Documents

Publication Publication Date Title
IL170601A (en) Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection
IL180947A0 (en) Vaccine for prevention and treatment of hiv infection
ZA200410229B (en) Administration of therapeutic viruses
TWI347189B (en) Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus
EP1594512A4 (en) COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTIONS
EP1492563A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIONS WITH THE HERPES SIMPLEX VIRUS
IL185376A0 (en) Use of a combination of myxoma virus and rapamycin for therapeutic treatment
AU2003225281A8 (en) Materials and methods for prevention and treatment of rna viral diseases
GB0329254D0 (en) Treatment of viral infections
IL162236A0 (en) Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
AU2003287145A1 (en) Interferon drug therapy for the treatment of viral diseases and liver fibrosis
AU9279601A (en) Compounds and methods for use thereof in the treatment of cancer or viral infections
EP1848418A4 (en) USE OF NORDIHYDROGUAIARETIC ACID DERIVATIVES FOR THE TREATMENT OF DRUG RESISTANT VIRAL AND MICROBIAL CANCERS AND INFECTIONS
FR12C0058I2 (fr) Medicament pour traiter des maladies de peau virales et des maladies tumorales
EP1525216A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF HIV INFECTION
EP1765330A4 (en) PYRANOINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DISEASE OR INFECTION CAUSED BY HEPATITIS C VIRUS
GB0329958D0 (en) Treatment of viral infections
NO20041855L (no) Fremgangsmate for behandling av hepatitt C-virusinfeksjon ved behandling av feilpasienter
AU2003299962A1 (en) Interferon drug therapy for the treatment of viral diseases and liver fibrosis
AU2003269133A1 (en) Combination treatment of cancer using a cancer vaccine and a chemotherapeutic drug
EP1482955A4 (en) PROPHYLACTIC AND THERAPEUTIC TREATMENT OF INFECTIOUS DISEASES AND OTHER DISEASES USING IMMUNO EFFECTOR COMPOUNDS
EP1744780A4 (en) CANCER TREATMENT USING VIRUSES AND CAMPTOTHECINS
AU2002327531A1 (en) Therapeutic compositions and methods for treating viral infection
AU2003287216A8 (en) Gb virus c and methods of treating viral infections
DK1150981T3 (da) Terapeutisk necleosidforbindelse

Legal Events

Date Code Title Description
KB Patent renewed